TY - JOUR
T1 - Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen
AU - Nakamura, Nobuhiko
AU - Goto, Naoe
AU - Tsurumi, Hisashi
AU - Takemura, Masao
AU - Kanemura, Nobuhiro
AU - Kasahara, Senji
AU - Hara, Takeshi
AU - Yasuda, Ichiro
AU - Shimizu, Masahito
AU - Sawada, Michio
AU - Yamada, Toshiki
AU - Seishima, Mitsuru
AU - Takami, Tsuyoshi
AU - Moriwaki, Hisataka
PY - 2013/10
Y1 - 2013/10
N2 - Background: Serum soluble tumor necrosis factor receptor 2 (sTNFR2) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma including diffuse large B-cell lymphoma (DLBCL) treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) in our previous study. However, after rituximab (R) was introduced in clinical practice, R-CHOP replaced CHOP as the standard therapy for DLBCL. Patients and methods: In this study, we re-evaluated the prognostic significance of serum sTNFR2 in 154 patients with DLBCL treated with R-CHOP. Results: Five-yr overall survival (5-yr OS) rates with sTNFR2 ≥20 ng/mL and <20 ng/mL were 29.2% and 83.3% (P < 0.0001), respectively, and the corresponding 5-yr progression-free survival (5-yr PFS) rates were 26.9% and 76.4% (P < 0.0001), respectively. A multivariate analysis revealed that serum sTNFR2 and complete remission (CR) were independent prognostic factors for both OS (CR: P < 0.0001, sTNFR2: P = 0.0001) and PFS (CR: P < 0.0001, sTNFR2: P = 0.0001). The prognosis of patients with poor risk groups according to the revised International Prognostic Index who also had high serum sTNFR2 was especially poor. Conclusion: Serum sTNFR2 might be a powerful prognostic factor for patients with DLBCL in the rituximab era.
AB - Background: Serum soluble tumor necrosis factor receptor 2 (sTNFR2) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma including diffuse large B-cell lymphoma (DLBCL) treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) in our previous study. However, after rituximab (R) was introduced in clinical practice, R-CHOP replaced CHOP as the standard therapy for DLBCL. Patients and methods: In this study, we re-evaluated the prognostic significance of serum sTNFR2 in 154 patients with DLBCL treated with R-CHOP. Results: Five-yr overall survival (5-yr OS) rates with sTNFR2 ≥20 ng/mL and <20 ng/mL were 29.2% and 83.3% (P < 0.0001), respectively, and the corresponding 5-yr progression-free survival (5-yr PFS) rates were 26.9% and 76.4% (P < 0.0001), respectively. A multivariate analysis revealed that serum sTNFR2 and complete remission (CR) were independent prognostic factors for both OS (CR: P < 0.0001, sTNFR2: P = 0.0001) and PFS (CR: P < 0.0001, sTNFR2: P = 0.0001). The prognosis of patients with poor risk groups according to the revised International Prognostic Index who also had high serum sTNFR2 was especially poor. Conclusion: Serum sTNFR2 might be a powerful prognostic factor for patients with DLBCL in the rituximab era.
UR - http://www.scopus.com/inward/record.url?scp=84884818031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884818031&partnerID=8YFLogxK
U2 - 10.1111/ejh.12139
DO - 10.1111/ejh.12139
M3 - Article
C2 - 23672298
AN - SCOPUS:84884818031
SN - 0902-4441
VL - 91
SP - 322
EP - 331
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 4
ER -